Meeting
2024 ASCO Annual Meeting
Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi.
Authors
Javid J. Moslehi
Section of Cardio-oncology and Immunology, University of California, San Francisco, San Francisco, CA
Javid J. Moslehi , Svea K Wahlstrom , Anna Teschemaker , Rachel H Mackey , Diana DeVincenzo , Leslie A Carabuena , Samantha L Thompson , Brittaney Gordon , Ning A Rosenthal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7052)
DOI
10.1200/JCO.2024.42.16_suppl.7052
Abstract #
7052
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of neoadjuvant chemotherapy on 30-day radical cystectomy outcomes.
First Author: Kerith Ruoyao Wang
First Author: Rishabh Simhal
Poster
2023 ASCO Annual Meeting
BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.
First Author: Michael Wang
Poster
2023 ASCO Annual Meeting
Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.
First Author: Fahmin Basher